{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Fcmv-antivirals-uMSiHEcY","width":444,"version":"1.0","type":"rich","title":"The Antiviral Angle: Leveraging the Full CMV Armamentarium","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/0d45af65-97a0-49b0-a714-d3baef0c4605/cco-100758-cmv-proph-pod2-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/138a27b7-b2a2-455c-bf33-7934f856af2e\" height=\"200\" width=\"100%\" title=\"The Antiviral Angle: Leveraging the Full CMV Armamentarium\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen in as Dr Marcus Pereira  discusses designing cytomegalovirus (CMV) antiviral regimens for high-risk kidney transplant recipients to mitigate the impact of infection while minimizing drug toxicities."}